Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

insulin icodec (Awiqli)

Therapeutic Area: Diabetes mellitus, type 2
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
 

Submit Feedback

bimekizumab (Bimzelx)

Therapeutic Area: Psoriatic arthritis
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
 

Submit Feedback

bimekizumab (Bimzelx)

Therapeutic Area: Ankylosing spondylitis
Draft recommendations posted for stakeholder feedback: April 18, 2024
End of feedback period: May 03, 2024
Draft Recommendation
 

Submit Feedback

Open Calls for Patient and Clinician Input